Honors Gallery

A lifesaving diagnostic test for cancer patients

Award: Excellence in Technology Transfer

Year: 2011

Award Type:

Region: Mid-Atlantic

National Cancer Institute (NCI)

Most people are aware that anti-cancer treatments often have negative side effects, but patients are willing to tolerate these side effects for the potential lifesaving effects of the treatment. However, some patients treated with the anti-cancer drug 5-Fluorouracil (5-FU) will have fatal reactions typically caused by cardio-toxicity. Scientists at the National Cancer Institute (NCI) have developed a lifesaving diagnostic test to identify cancer patients that may experience 5-FU toxicity, thus making it possible to avoid 5-FU toxicity by using this diagnostic screening test prior to the administration of 5-FU.

The diagnostic test is based on screening for a mutation in the dihydropyrimidine dehydrogenase (DPD) gene. DPD is involved with the degradation of 5-FU, and it has been shown that patients exhibiting 5-FU toxicity have low DPD activity levels. In 1994, the NCI team determined the molecular basis (a splicing mutation) for the DPD deficiency observed in patients with 5-FU toxicity and developed a method to detect the mutation. Since then, this discovery has been translated into multiple commercial products that detect the mutation and allow health care providers to provide optimal anti-cancer treatment.

5-FU is used for the treatment of multiple cancers, including breast and colon. In the United States, approximately 275,000 cancer patients receive 5-FU annually. It is estimated that 3% of those patients develop some degree of toxic reaction, and approximately 15% of those will die as a result of exposure to 5-FU. In the United States alone, more than 1,300 patients die each year as a result of 5-FU toxicity. These deaths are all potentially avoidable if patients are screened prior to the administration of 5-FU using the diagnostic test developed by NCI.

This technology has been licensed nonexclusively to several licensees. The transfer of this technology through these nonexclusive licenses has enabled the wide dissemination of this test in the United States and Europe. As a result of these multiple licenses, many more people around the globe can forego being treated by a drug that may prove to do more harm than good. The wide dissemination of this lifesaving diagnostic test promotes the NIH mission of improving public health.